Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH5-AS
- Development stage
- Unknown
- Lead developer
- Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CH5-AS is an avian influenza vaccine candidate targeting the H5 subtype, specifically the highly pathogenic avian influenza virus (HPAIV) H5N8 clade 2.3.4.4b. It is being developed as part of Japan's pandemic preparedness strategy by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) and the Japan Agency for Medical Research and Development (AMED). The vaccine is designed to elicit protective immune responses against the hemagglutinin (HA) protein of the virus. In clinical trials, it is administered as a two-dose intramuscular injection to healthy adults to evaluate its safety and immunogenicity, with the goal of establishing a stockpile or rapid response capability for potential H5 clade 2.3.4.4b pandemics.
- Other names
- H5N8 avian influenza vaccineH-5N8 avian influenza vaccineH 5N8 avian influenza vaccineHPAIV H5N8 vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on CH5-AS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH5-AS.